Catalyst Dossier · compiled by CeliA 🧫

IQVIA HOLDINGS INC. (IQV)

Services-Commercial Physical & Biological Research · market cap $28.0B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

IQVIA Holdings (IQV) is a global contract research organization (CRO) and health information technology company with $16.3B in 2025 revenue and ~93,000 employees, serving pharma, biotech, and medical device clients. The company carries a heavy net debt load of $13.9B against $1.9B in cash. The immediate catalyst is a Q2 2026 earnings release on July 28, rated modest importance (5/10).

The catalyst path

2026-11-05 (est.)Phase 2 · Bedaquiline, pretomanid and TBD09imp 7/10
2026-12-26 (est.)Phase 3 · Oregovomabimp 9/10
2027-01-30 (est.)Phase 2 · Ixovex-1imp 7/10
2027-02-15 (est.)Phase 2 · ER004imp 7/10

Pipeline

Asset	Phase	Indication
Oregovomab	Phase 3	Carcinoma, Ovarian Epithelial
Futibatinib	Phase 2	Advanced Solid Tumor
Humira 40 MG in Prefilled Syringe	Phase 3	Moderate Chronic Plaque Psoriasis
Namilumab	Phase 2	Axial Spondyloarthritis
GSK3196165 (Otilimab)	Phase 3	Arthritis, Rheumatoid
FP-101	Phase 2	Hot Flashes
Olokizumab 64 mg SC q4w	Phase 3	Rheumatoid Arthritis
Recombinant human alpha galactosidase A (agalsidase beta)	Phase 3	Fabry Disease
Benralizumab	Phase 3	Severe Uncontrolled Asthma
Propagermanium	Phase 2	Focal Segmental Glomerulosclerosis
GSK3511294 (Depemokimab)	Phase 3	Asthma
BB2603-1	Phase 2	Distal Subungual Onychomycosis
Nirsevimab	Phase 2	RSV Infection
Belantamab mafodotin	Phase 2	Multiple Myeloma
Ixovex-1	Phase 2	Solid Tumor
Etripamil NS	Phase 3	Paroxysmal Supraventricular Tachycardia
ER004	Phase 2	X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
HBI-8000	Phase 2	Adult T-Cell Lymphoma (ATL)
Efgartigimod	Phase 2	Primary Sjögren's Syndrome
Tapinarof	Phase 3	Plaque Psoriasis

Price & technical context

3-month

+38.7%

6-month

+40.2%

12-month

+24.4%

52-wk range

$156.66–$247.56

vs 50-day MA

+14.6%

vs 200-day MA

+19.1%

Realized vol

41.1%

Max drawdown

-45.5%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IQV (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.